Benefit for once-daily Xarelto in the first trial to evaluate prospective use in AF patients undergoing cardioversion

2 September 2014

German pharma and chemical major Bayer (BAYN: DE) has released results from the X-VeRT* study, demonstrating that once-daily Xarelto(rivaroxaban) is an effective and well-tolerated alternative to dose-adjusted vitamin K antagonists (VKAs) such as warfarin, in patients with non-valvular atrial fibrilation (AF) undergoing cardioversion, which may also allow for more timely cardioversion.

The new data on Xarelto, Bayer’s blockbuster blood thinner that generated sales of around $1.7 billion in the 12 months to June 2014, were presented at the European Society of Cardiology (ESC) congress taking place in Barcelona, Spain.

Positive comparison with warfarin

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK